Kymera Therapeutics, Inc.

Equities

KYMR

US5015751044

Real-time Estimate Cboe BZX Other stock markets 20:07:17 12/05/2026 BST			5-day change	1st Jan Change
82.42 ^USD	-1.99%		+0.19%	+6.50%

05-06	Canaccord Genuity Initiates Kymera Therapeutics at Buy With $106 Price Target	MT
05-05	Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, A First-In-Class, Oral Irf5 Degrader, At Digestive Disease Week	CI

Transcript : Kymera Therapeutics, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-12-2026 09

Published on 03/12/2026 at 03:35 pm GMT - Modified on 03/12/2026 at 05:05 pm GMT

S&P Capital IQ

Presenter Speech
Eliana Merle (Analysts)

Good morning, everyone. Thanks for joining us on the final day of the Barclays Global Healthcare Conference here in Miami. I'm Ellie Merle. Very excited to have

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Kymera Therapeutics, Inc.

05-06	Canaccord Genuity Initiates Kymera Therapeutics at Buy With $106 Price Target	MT
05-05	Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, A First-In-Class, Oral Irf5 Degrader, At Digestive Disease Week	CI
04-30	Kymera Therapeutics, Inc., Q1 2026 Earnings Call, Apr 30, 2026
04-30	Kymera Therapeutics Shares Fall After Q1 Loss Narrows, Collaboration Revenue Rises	MT
04-30	Kymera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-30	Earnings Flash (KYMR) Kymera Therapeutics Posts Q1 Net Loss $0.71 a Share, vs. FactSet Est of $0.88 Loss	MT
04-30	Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q1 Revenue $34.4M, vs. FactSet Est of $8.3M	MT
04-13	Kymera Therapeutics Wins FDA Fast Track for Oral Asthma Drug	MT
04-13	Kymera Therapeutics, Inc. Announces U.S. FDA Fast Track Designation for KT-621, A First-In-Class, Oral Stat6 Degrader for the Treatment of Moderate to Severe Asthma	CI
04-09	Kymera to Receive $45 Million Milestone Payment as Gilead Exercises Option to License KT-200	MT
04-09	Kymera Therapeutics announces Gilead Sciences' option exercise to license KT-200, oral CDK2 molecular glue degrader development candidate	RE
04-09	Kymera Therapeutics and Gilead Sciences Enter License Agreement for Kt-200 with $45 Million Milestone Payment	CI
03-28	Kymera Therapeutics Presents KT-621 BroADen Data In Late-Breaking Research Session At The American Academy Of Dermatology Annual Meeting	CI
03-12	Kymera Therapeutics, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-12-2026 09:30 AM
03-03	UBS Adjusts Price Target on Kymera Therapeutics to $128 From $90, Maintains Buy Rating	MT